Ref.
2023/CG/9501
Job offer type
Experts
Type of contract
Service contract
Activity sectors
Non communicable diseases ; Health policy ; Health systems
Sub-theme
Cancer
Deadline date
2023/06/05 23:59
Duration of the assignment
Short term
Contract
Freelancer
Duration
3 mois
Département Santé - DEPSAN > Pôle Initiative 5% et Pandémies
Published on : 2023/05/25
Objectives of the consultancy:
Job Description:
The SUCCESS project will be engaging a consultant to conduct a data collection exercise to work with other team members to collect the data needed for the cost study.
The consultant will be responsible for the following:
Products
Final consulting report including:
Confidentiality of information and intellectual property
The contracted company and its personnel undertake to carry out the assigned tasks in accordance with the highest standards of ethical competence and professional integrity. All data collected and databases are confidential, and therefore may not be shared or used in other media by the consulting team.
The ownership, title and industrial and intellectual property rights of the results of the consultancy, as well as of the reports and other documents produced, are the property of the SUCCESS Project.
At the beginning of the process, the team must sign a confidentiality and intellectual property agreement.
Expected execution period:
Introduction:
Cervical cancer is one of the most common preventable forms of cancer, but it is the fourth most common cancer among women globally and the leading cause of death among HIV-infected women. [1],[2],[3] An estimated 604,127 new cases of cervical cancer were diagnosed worldwide and 341,831 women died from the disease in 2020. An overwhelming majority (90%) of these cervical cancer deaths occur in low- and middle-income countries (LMICs), which often have poor health infrastructure.[4] Nearly all cases of cervical cancer (99%) are related to infection with high-risk human papillomavirus (HPV), an extremely common virus transmitted through sexual contact.[5],[6]
To address this situation, the World Health Organization (WHO) has launched a strategy to accelerate the elimination of cervical cancer worldwide. This strategy aims to ensure that, by 2030, 90% of girls are vaccinated against HPV, 90% of adult women have access to screening services with a highly effective test, and 70% of women with cancer or precancerous lesions receive the treatment they need.
In Guatemala, cervical cancer continues to be the second most frequent cancer among women, and the leading cause of cancer deaths in women. It is estimated that 872 women die each year, and 1,555 new cases are detected.4 For this reason, the State of Guatemala, through the Ministry of Health and Social Assistance, has joined this initiative and updated its Comprehensive Care Guide for the prevention, detection and treatment of cervical cancer precursor lesions, which includes guidelines for vaccination against HPV, the offer of screening tests including Pap smears, Visual Inspection with Acetic Acid and HPV DNA tests, and finally guidance on methods of precursor or precancerous lesions.
WHO estimates that a total of USD 10.5 billion is required to finance cervical cancer eradication in low- and low-to-middle-income countries by 2030, where a large portion of this amount (equivalent to USD 1.8 per capita) should be frontloaded to rapidly establish and scale up services; 6.2 USD of this figure is needed for vaccination programs; 2.1 USD for facility utilization; 1.3 USD for consumables, 0.5 USD for human resources and 0.4 USD for equipment; by 2019 TogetHER for Health, reported that only one-seventh of this amount was invested in these countries[7] .
In this context, the SUCCESS (Scale up cervical cancer elimination with secondary prevention strategy) project is supporting four countries (Guatemala, Burkina Faso, Côte d'Ivoire and the Philippines) to expand their screening programs with an emphasis on HPV DNA testing and ablative treatment of precancerous cervical lesions as part of their interventions, the project plans to estimate the costs of implementing cervical cancer prevention interventions over a 5-year period in each of the implementing countries and, in the case of Guatemala, involves an exercise to estimate the costs of integrating secondary prevention (screening) and tertiary prevention (early treatment of precancerous lesions) into the continuum of care through services integrated into MSPAS health facilities; this also includes a comparative analysis of costs in different potential scenarios. This is part of a transition plan that will allow MSPAS, to optimize national funds and other sources of funding in the financing of screening and ablative treatment services, through a phased implementation in its network of services.
This exercise will be conducted using an adapted version of the Costing Tool for Cervical Cancer Prevention and Control (C4P), developed for WHO. This tool is intended for use by LMIC program managers to plan cervical cancer control strategies and make multi-year cost projections. It uses a bottom-up, input-based approach (i.e., unit cost X quantity of good or service). The C4P-SUCCESS tool will reflect the country's screening and treatment algorithm.
These costs will include two broad categories:
[1]World Health Organization. Global strategy for accelerating the elimination of cervical cancer as a public health problem and its associated goals and targets for the period 2020-2030. Vol 2.; 2020.
[2] World Health Organization. Analysis and use of data from health facilities: guidance for HIV program managers.; 2018. https://www.who.int/healthinfo/FacilityAnalysisGuide_HIV.pdf
[3] Kelly HA, Sawadogo B, Chikandiwa A, et al. Epidemiology of high-risk human papillomavirus and cervical lesions in African women living with HIV/AIDS: effect of antiretroviral therapy. AIDS. 2017;31(2):273-285.
[4] UICC. GLOBOCAN 2020: New Global Cancer Data.; 2020. https://www.uicc.org/news/globocan-2020-new-global-cancer-data.
[5] UICC. GLOBOCAN 2020: New Global Cancer Data; 2020. https://www.uicc.org/news/globocan-2020-new-global-cancer-data. https://www.uicc.org/news/globocan-2020-new-global-cancer-data.
[6]Castle PE, Glass AG, Rush BB, et al. Clinical detection of human papillomavirus predicts cervical cancer risk in women over 18 years of follow-up. J Clin Oncol. 2012;30(25):3044-3050. doi:10.1200/JCO.2011.38.8389.
[7] WHO and Together for Health, 2020 (The Economist Intelligence Unit Limited 2021. UICC, Expertise France, Unitaid).
Required qualifications:
Professional skills:
Liaison:
Employed by:
Reporting to:
We invite qualified candidates to please submit a CV and a cover letter., both in English and Spanish.
The selection process for candidates will be based on the following criteria :
Deadline for application : 2023/06/05 23:59